The potential health effects of dietary phytoestrogens

British Journal of Pharmacology

Volumn 174, Issue 11, 2017, Pages 1263-1280

  Rietjens, Ivonne M C M ^a   Louisse, Jochem ^a   Beekmann, Karsten ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT;

BRAIN DISEASE; BREAST CANCER; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; DIETARY INTAKE; HUMAN; INTESTINE CANCER; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; ANIMAL; CHEMISTRY; DIET; DIETARY SUPPLEMENT; METABOLISM;

ANIMALS; DIET; DIETARY SUPPLEMENTS; HUMANS; PHYTOESTROGENS; PLANT PREPARATIONS; RECEPTORS, ESTROGEN;

EID: 84991628424     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13622     Document Type: Review

References (231)

1. Adlercreutz H (1995). Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 103 (Suppl 7): 103–112.
2. Adlercreutz H (2002). Phyto-oestrogens and cancer. Lancet Oncol 3: 364–373.
3. Adlercreutz H (2007). Lignans and human health. Crit Rev Clin Lab Sci 44: 483–525.
4. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T et al. (2004). Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34: 86–89.
5. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
6. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
7. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
8. Ali S, Coombes RC (2000). Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5: 271–281.
9. Anderson LN, Cotterchio M, Boucher BA, Kreiger N (2013). Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women. Int J Cancer 132: 1683–1692.
10. Andres S, Abraham K, Appel KE, Lampen A (2011). Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 41: 463–506.
11. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS et al. (2004). Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Res 6: R170–R179.
12. Azcoitia I, Moreno A, Carrero P, Palacios S, Garcia-Segura LM (2006). Neuroprotective effects of soy phytoestrogens in the rat brain. Gynecol Endocrinol 22: 63–69.
13. Bagheri M, Roghani M, Joghataei MT, Mohseni S (2012). Genistein inhibits aggregation of exogenous amyloid-beta(1)(−)(4)(0) and alleviates astrogliosis in the hippocampus of rats. Brain Res 1429: 145–154.
14. Bansal N, Parle M (2010). Soybean supplementation helps reverse age- and scopolamine-induced memory deficits in mice. J Med Food 13: 1293–1300.
15. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004). Loss of ER beta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11: 537–551.
16. Barnes S, Peterson TG, Coward L (1995). Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate-cancer. J Cell Biochem : 181–187.
17. Beekmann K, de Haan LH, Actis-Goretta L, Houtman R, van Bladeren PJ, Rietjens IM (2015). The effect of glucuronidation on isoflavone induced estrogen receptor (ER)alpha and ERbeta mediated coregulator interactions. J Steroid Biochem Mol Biol 154: 245–253.
18. Bennetts HW, Underwood EJ, Shier FL (1946). A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust Vet J 22: 2–12.
19. Bhathena SJ, Velasquez MT (2002). Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76: 1191–1201.
20. Bolanos R, Del Castillo A, Francia J (2010). Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause (New York, NY) 17: 660–666.
21. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999). Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155: 641–647.
22. Boucher BA, Cotterchio M, Anderson LN, Kreiger N, Kirsh VA, Thompson LU (2013). Use of isoflavone supplements is associated with reduced postmenopausal breast cancer risk. Int J Cancer 132: 1439–1450.
23. Boue SM, Burow ME, Wiese TE, Shih BY, Elliott S, Carter-Wientjes CH et al. (2011). Estrogenic and antiestrogenic activities of phytoalexins from red kidney bean (Phaseolus vulgaris L.). J Agric Food Chem 59: 112–120.
24. Bovee TF, Helsdingen RJ, Rietjens IM, Keijer J, Hoogenboom RL (2004). Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol 91: 99–109.
25. Brasky TM, Lampe JW, Potter JD, Patterson RE, White E (2010). Specialty supplements and breast cancer risk in the VITamins and Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev 19: 1696–1708.
26. Brinton RD (2004). Impact of estrogen therapy on Alzheimer's disease: a fork in the road? CNS Drugs 18: 405–422.
27. Buck K, Zaineddin AK, Vrieling A, Linseisen J, Chang-Claude J (2010). Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr 92: 141–153.
28. Buck K, Zaineddin AK, Vrieling A, Heinz J, Linseisen J, Flesch-Janys D et al. (2011). Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 105: 1151–1157.
29. Cano A, Garcia-Perez MA, Tarin JJ (2010). Isoflavones and cardiovascular disease. Maturitas 67: 219–226.
30. Casanova M, You L, Gaido KW, Archibeque-Engle S, Janszen DB, Heck HA (1999). Developmental effects of dietary phytoestrogens in Sprague–Dawley rats and interactions of genistein and daidzein with rat estrogen receptors alpha and beta in vitro. Toxicol Sci 51: 236–244.
31. Casini ML, Marelli G, Papaleo E, Ferrari A, D'Ambrosio F, Unfer V (2006). Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril 85: 972–978.
32. Cederroth CR, Nef S (2009). Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 304: 30–42.
33. Chang HC, Doerge DR (2000). Dietary genistein inactivates rat thyroid peroxidase in vivo without an apparent hypothyroid effect. Toxicol Appl Pharmacol 168: 244–252.
34. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA et al. (2008). Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol 22: 1032–1043.
35. Chen M, Rao Y, Zheng Y, Wei S, Li Y, Guo T et al. (2014). Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies. PLoS One 9: e89288.
36. Chen MN, Lin CC, Liu CF (2015). Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 18: 260–269.
37. Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM (2007). Isoflavone treatment for acute menopausal symptoms. Menopause (New York, N.Y.) 14: 468–473.
38. Choi EJ, Lee BH (2004). Evidence for genistein mediated cytotoxicity and apoptosis in rat brain. Life Sci 75: 499–509.
39. Chrzan BG, Bradford PG (2007). Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res 51: 171–177.
40. Chu WL, Shiizaki K, Kawanishi M, Kondo M, Yagi T (2009). Validation of a new yeast-based reporter assay consisting of human estrogen receptors alpha/beta and coactivator SRC-1: application for detection of estrogenic activity in environmental samples. Environ Toxicol 24: 513–521.
41. Colacurci N, De Franciscis P, Atlante M, Mancino P, Monti M, Volpini G et al. (2013). Endometrial, breast and liver safety of soy isoflavones plus lactobacillus sporogenes in post-menopausal women. Gynecol Endocrinol 29: 209–212.
42. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987). Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105–1110.
43. Crespillo A, Alonso M, Vida M, Pavon FJ, Serrano A, Rivera P et al. (2011). Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. Br J Pharmacol 164: 1899–1915.
44. De Angelis M, Stossi F, Waibel M, Katzenellenbogen BS, Katzenellenbogen JA (2005). Isocoumarins as estrogen receptor beta selective ligands: isomers of isoflavone phytoestrogens and their metabolites. Bioorg Med Chem 13: 6529–6542.
45. de Kleijn MJJ, van der Schouw YT, Wilson PWF, Grobbee DE, Jacques PF (2002). Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal US women: the Framingham study. J Nutr 132: 276–282.
46. Delmanto A, Nahas-Neto J, Traiman P, Uemura G, Pessoa EC, Nahas EA (2013). Effects of soy isoflavones on mammographic density and breast parenchyma in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial. Menopause (New York, N.Y.) 20: 1049–1054.
47. Dhooghe L, Naessens T, Heyerick A, De Keukeleire D, Vlietinck AJ, Pieters L et al. (2010). Quantification of xanthohumol, isoxanthohumol, 8-prenylnaringenin, and 6-prenylnaringenin in hop extracts and derived capsules using secondary standards. Talanta 83: 448–456.
48. Ding D, Xu L, Fang H, Hong H, Perkins R, Harris S et al. (2010). The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics 11 (Suppl 6): S5.
49. Divi RL, Chang HC, Doerge DR (1997). Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. Biochem Pharmacol 54: 1087–1096.
50. Djiogue S, Halabalaki M, Njamen D, Kretzschmar G, Lambrinidis G, Hoepping J et al. (2014). Erythroidine alkaloids: a novel class of phytoestrogens. Planta Med 80: 861–869.
51. Doerge DR, Sheehan DM (2002). Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect 110 (Suppl 3): 349–353.
52. Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL (2006). Maternal genistein alters coat color and protects A(vy) mouse offspring from obesity by modifying the fetal epigenome. Environ Health Persp 114: 567–572.
53. Dong JY, Qin LQ (2011). Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 125: 315–323.
54. Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A (2001). Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 78: 67–75.
55. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ (1999). Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 33: 177–182.
56. Duffy R, Wiseman H, File SE (2003). Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav 75: 721–729.
57. Eden JA (2012). Phytoestrogens for menopausal symptoms: a review. Maturitas 72: 157–159.
58. EFSA ANS Panel (2015). Scientific opinion on the risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA J 13: 342.
59. EFSA NDA Panel (2012). Scientific opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 10: 2847.
60. Eisenbrand G, Senate Commission on Food Safety of the German Research F (2007). Isoflavones as phytoestrogens in food supplements and dietary foods for special medical purposes. Opinion of the Senate Commission on Food Safety (SKLM) of the German Research Foundation (DFG)-(shortened version). Mol Nutr Food Res 51: 1305–1312.
61. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G et al. (1997). Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82: 4258–4265.
62. Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P et al. (2006). Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem Pharmacol 71: 1459–1469.
63. Evers NM, van den Berg JH, Wang S, Melchers D, Houtman R, de Haan LH et al. (2014a). Cell proliferation and modulation of interaction of estrogen receptors with coregulators induced by ERalpha and ERbeta agonists. J Steroid Biochem Mol Biol 143: 376–385.
64. Evers NM, Wang S, van den Berg JH, Houtman R, Melchers D, de Haan LH et al. (2014b). Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant. Chem Biol Interact 220: 222–230.
65. Fang K, Dong H, Wang H, Gong J, Huang W, Lu F (2016). Soy isoflavones and glucose metabolism in menopausal women: A systematic review and meta-analysis of randomized controlled trials. Mol Nutr Food res 60: 1602–1614.
66. File SE, Jarrett N, Fluck E, Duffy R, Casey K, Wiseman H (2001). Eating soya improves human memory. Psychopharmacology (Berl) 157: 430–436.
67. Franco OH, Burger H, Lebrun CEI, Peeters PHM, Lamberts SWJ, Grobbee DE et al. (2005). Higher dietary intake of lignans is associated with better cognitive performance in postmesopausal women. J Nutr 135: 1190–1195.
68. Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S et al. (2013). Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One 8: e81968.
69. Gennari L, Merlotti D, De Paola V, Calabro A, Becherini L, Martini G et al. (2005). Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Am J Epidemiol 161: 307–320.
70. Giridharan VV, Thandavarayan RA, Sato S, Ko KM, Konishi T (2011). Prevention of scopolamine-induced memory deficits by schisandrin B, an antioxidant lignan from Schisandra chinensis in mice. Free Radic Res 45: 950–958.
71. Gleason CE, Carlsson CM, Barnet JH, Meade SA, Setchell KD, Atwood CS et al. (2009). A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age Ageing 38: 86–93.
72. Gonzalez Canete N, Duran Aguero S (2014). Soya isoflavones and evidences on cardiovascular protection. Nutr Hosp 29: 1271–1282.
73. Goodman MT, Shvetsov YB, Wilkens LR, Franke AA, Le Marchand L, Kakazu KK et al. (2009). Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Prev Res (Phila) 2: 887–894.
74. Gorodeski GI (1994). Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol 29: 357–375.
75. Greendale GA, Huang MH, Leung K, Crawford SL, Gold EB, Wight R et al. (2012). Dietary phytoestrogen intakes and cognitive function during the menopausal transition: results from the study of women's health across the nation phytoestrogen study. Menopause (New York, N.Y.) 19: 894–903.
76. Greendale GA, Tseng CH, Han W, Huang MH, Leung K, Crawford S et al. (2015). Dietary isoflavones and bone mineral density during midlife and the menopausal transition: cross-sectional and longitudinal results from the Study of Women's Health Across the Nation Phytoestrogen Study. Menopause (New York, N.Y.) 22: 279–288.
77. Gutendorf B, Westendorf J (2001). Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology 166: 79–89.
78. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA et al. (1999). Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocr Metab 84: 4017–4024.
79. Harris HA (2007). Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol 21: 1–13.
80. Harris DM, Besselink E, Henning SM, Go VL, Heber D (2005). Phytoestrogens induce differential estrogen receptor alpha- or Beta-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood) 230: 558–568.
81. Haselkorn T, Stewart SL, Horn-Ross PL (2003). Why are thyroid cancer rates so high in southeast asian women living in the United States? The bay area thyroid cancer study. Canc Epidemiol Biomarkers Prev 12: 144–150.
82. He J, Wang S, Zhou M, Yu W, Zhang Y, He X (2015). Phytoestrogens and risk of prostate cancer: a meta-analysis of observational studies. World J Surg Oncol 13: 231.
83. Hilakivi-Clarke L, Andrade JE, Helferich W (2010). Is soy consumption good or bad for the breast? J Nutr 140: 2326S–2334S.
84. Hogervorst E, Sadjimim T, Yesufu A, Kreager P, Rahardjo TB (2008). High tofu intake is associated with worse memory in elderly Indonesian men and women. Dement Geriatr Cogn Disord 26: 50–57.
85. Hogervorst E, Mursjid F, Priandini D, Setyawan H, Ismael RI, Bandelow S et al. (2011). Borobudur revisited: soy consumption may be associated with better recall in younger, but not in older, rural Indonesian elderly. Brain Res 1379: 206–212.
86. Horn-Ross PL, Hoggatt KJ, Lee MM (2002). Phytoestrogens and thyroid cancer risk: the San Francisco Bay area thyroid cancer study. Canc Epidemiol Biomarkers Prev 11: 43–49.
87. Howes LG, Howes JB, Knight DC (2006). Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas 55: 203–211.
88. Hsu MH, Savas U, Lasker JM, Johnson EF (2011). Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. J Pharmacol Exp Ther 337: 125–136.
89. Hu D, Cao Y, He R, Han N, Liu Z, Miao L et al. (2012). Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Abeta1-42-induced memory impairment in mice. Oxid Med Cell Longev 2012: 721721.
90. Huang YH, Zhang QH (2010). Genistein reduced the neural apoptosis in the brain of ovariectomised rats by modulating mitochondrial oxidative stress. Br J Nutr 104: 1297–1303.
91. Hughes CL Jr (1988). Phytochemical mimicry of reproductive hormones and modulation of herbivore fertility by phytoestrogens. Environ Health Perspect 78: 171–174.
92. Hullar MA, Lancaster SM, Li F, Tseng E, Beer K, Atkinson C et al. (2015). Enterolignan-producing phenotypes are associated with increased gut microbial diversity and altered composition in premenopausal women in the United States. Canc Epidemiol Biomarkers Prev 24: 546–554.
93. Hwang JT, Park IJ, Shin JI, Lee YK, Lee SK, Baik HW et al. (2005). Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 338: 694–699.
94. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM (2009). Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 61: 598–606.
95. Ikeda K, Arao Y, Otsuka H, Nomoto S, Horiguchi H, Kato S et al. (2002). Terpenoids found in the umbelliferae family act as agonists/antagonists for ER(alpha) and ERbeta: differential transcription activity between ferutinine-liganded ER(alpha) and ERbeta. Biochem Biophys Res Commun 291: 354–360.
96. Ingram D, Sanders K, Kolybaba M, Lopez D (1997). Case–control study of phyto-oestrogens and breast cancer. Lancet 350: 990–994.
97. Islam MA, Bekele R, Van den Berg JH, Kuswanti Y, Thapa O, Soltani S et al. (2015). Deconjugation of soy isoflavone glucuronides needed for estrogenic activity. Toxicol In Vitro 29: 706–715.
98. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A (2009). Efficacy of isoflavones in relieving vasomotor menopausal symptoms – a systematic review. Mol Nutr Food Res 53: 1084–1097.
99. Jeong EJ, Lee HK, Lee KY, Jeon BJ, Kim DH, Park JH et al. (2013). The effects of lignan-riched extract of Shisandra chinensis on amyloid-beta-induced cognitive impairment and neurotoxicity in the cortex and hippocampus of mouse. J Ethnopharmacol 146: 347–354.
100. Jungbauer A, Medjakovic S (2014). Phytoestrogens and the metabolic syndrome. J Steroid Biochem Mol Biol 139: 277–289.
101. Kang NJ, Lee KW, Rogozin EA, Cho YY, Heo YS, Bode AM et al. (2007). Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 282: 32856–32866.
102. Karahalil B (2005). Benefits and Risks of Phytoestrogens. In: Yildiz F (ed). Phytoestrogens In Functional Foods. CRC Press: Boca Raton, FL, USA, pp. 210–211.
103. Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D et al. (2012). Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 5: 309–319.
104. Kim S-H, Kim S-H, Kim Y-B, Jeon Y-T, Lee S-C, Song Y-S (2009). Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann N Y Acad Sci 1171: 495–500.
105. King RA, Bursill DB (1998). Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67: 867–872.
106. Ko KP, Park SK, Park B, Yang JJ, Cho LY, Kang C et al. (2010). Isoflavones from phytoestrogens and gastric cancer risk: a nested case–control study within the Korean Multicenter Cancer Cohort. Canc Epidemiol Biomarkers Prev 19: 1292–1300.
107. Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S et al. (2007). Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation 116: 2553–2562.
108. Koo J, Cabarcas-Petroski S, Petrie JL, Diette N, White RJ, Schramm L (2015). Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. BMC Cancer 15: 905.
109. Korde L, Fears T, Wu A, Nomura A, West D, Pike M et al. (2004). Adolescent and childhood soy intake and breast cancer risk in Asian-American women. Breast Cancer Res Tr 88: S149–S149.
110. Korde LA, Wu AH, Fears T, Nomura AM, West DW, Kolonel LN et al. (2009). Childhood soy intake and breast cancer risk in Asian American women. Canc Epidemiol Biomarkers Prev 18: 1050–1059.
111. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW et al. (2004). Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 292: 65–74.
112. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, van der Schouw YT (2007). Dietary phytoestrogen intake and cognitive function in older women. J Gerontol A Biol Sci Med Sci 62: 556–562.
113. Kritz-Silverstein D, Von Muhlen D, Barrett-Connor E, Bressel MA (2003). Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health in Aging (SOPHIA) Study. Menopause (New York, N.Y.) 10: 196–202.
114. Kuijsten A, Arts ICW, Vree TB, Hollman PCH (2005). Pharmacokinetics of enterolignans in healthy men and women consuming a single dose of secoisolariciresinol diglucoside. J Nutr 135: 795–801.
115. Kuiper GGJM, Enmark E, PeltoHuikko M, Nilsson S, Gustafsson JA (1996). Cloning of a novel estrogen receptor expressed in rat prostate and ovary. P Natl Acad Sci USA 93: 5925–5930.
116. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT et al. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252–4263.
117. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S et al. (2007). Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Canc Epidemiol Biomarkers Prev 16: 538–545.
118. Kwack SJ, Kim KB, Kim HS, Yoon KS, Lee BM (2009). Risk assessment of soybean-based phytoestrogens. J Toxicol Environ Health A 72: 1254–1261.
119. Lahiry P, Torkamani A, Schork NJ, Hegele RA (2010). Kinase mutations in human disease: interpreting genotype–phenotype relationships. Nat Rev Genet 11: 60–74.
120. Lampe JW (2003). Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 133: 956S–964S.
121. Lee SA, Shu XO, Li H, Yang G, Cai H, Wen W et al. (2009). Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr 89: 1920–1926.
122. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J (2007). Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev : Cd001395.
123. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J (2013). Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev: Cd001395.
124. Li X, Zhao X, Xu X, Mao X, Liu Z, Li H et al. (2014). Schisantherin A recovers Abeta-induced neurodegeneration with cognitive decline in mice. Physiol Behav 132: 10–16.
125. Liu X, Nam JW, Song YS, Viswanath AN, Pae AN, Kil YS et al. (2014). Psoralidin, a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia. Bioorg Med Chem Lett 24: 1403–1406.
126. Lyn-Cook BD, Blann E, Payne PW, Bo J, Sheehan D, Medlock K (1995). Methylation profile and amplification of proto-oncogenes in rat pancreas induced with phytoestrogens. Proc Soc Exp Biol Med 208: 116–119.
127. Maffini MV, Rubin BS, Sonnenschein C, Soto AM (2006). Endocrine disruptors and reproductive health: the case of bisphenol-A. Mol Cell Endocrinol 254-255: 179–186.
128. Magee PJ (2011). Is equol production beneficial to health? Proc Nutr Soc 70: 10–18.
129. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002). The protein kinase complement of the human genome. Science (New York, NY) 298: 1912–1934.
130. Mao X, Liao Z, Guo L, Xu X, Wu B, Xu M et al. (2015). Schisandrin C ameliorates learning and memory deficits by abeta-induced oxidative stress and neurotoxicity in mice. Phytother Res 29: 1373–1380.
131. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M et al. (2007). Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 146: 839–847.
132. Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V et al. (2008). Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab 93: 4787–4796.
133. Maskarinec G, Verheus M, Steinberg FM, Amato P, Cramer MK, Lewis RD et al. (2009). Various doses of soy isoflavones do not modify mammographic density in postmenopausal women. J Nutr 139: 981–986.
134. Mense SM, Hei TK, Ganju RK, Bhat HK (2008). Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect 116: 426–433.
135. Messina M (2008). Conclusion that isoflavones exert estrogenic effects on breast tissue and may raise breast cancer risk unfounded. Mol Nutr Food Res 52: 299–300.
136. Molzberger AF, Soukup ST, Kulling SE, Diel P (2013). Proliferative and estrogenic sensitivity of the mammary gland are modulated by isoflavones during distinct periods of adolescence. Arch Toxicol 87: 1129–1140.
137. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N et al. (2002). Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 17: 1904–1912.
138. Moran J, Garrido P, Alonso A, Cabello E, Gonzalez C (2013). 17beta-Estradiol and genistein acute treatments improve some cerebral cortex homeostasis aspects deteriorated by aging in female rats. Exp Gerontol 48: 414–421.
139. Morrison JH, Brinton RD, Schmidt PJ, Gore AC (2006). Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 26: 10332–10348.
140. Mueller SO, Simon S, Chae K, Metzler M, Korach KS (2004). Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80: 14–25.
141. Nagata C (2000). Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int J Epidemiol 29: 832–836.
142. Nedrow A, Miller J, Walker M, Nygren P, Huffman LH, Nelson HD (2006). Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 166: 1453–1465.
143. Neese SL, Korol DL, Katzenellenbogen JA, Schantz SL (2010). Impact of estrogen receptor alpha and beta agonists on delayed alternation in middle-aged rats. Horm Behav 58: 878–890.
144. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G et al. (2001). Mechanisms of estrogen action. Physiol Rev 81: 1535–1565.
145. Nooyens AC, Milder IE, van Gelder BM, Bueno-de-Mesquita HB, van Boxtel MP, Verschuren WM (2015). Diet and cognitive decline at middle age: the role of antioxidants. Br J Nutr 113: 1410–1417.
146. Nott SL, Huang Y, Fluharty BR, Sokolov AM, Huang M, Cox C et al. (2008). Do estrogen receptor beta polymorphisms play a role in the pharmacogenetics of estrogen signaling? Curr Pharmacogenomics Person Med 6: 239–259.
147. NTP (2008). Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague–Dawley rats (feed study). Natl Toxicol Program Tech Rep Ser : 1–240.
148. Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M et al. (2009). The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case–control study. Canc Epidemiol Biomarkers Prev 18: 2207–2213.
149. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y et al. (1998). Molecular cloning and characterization of human estrogen receptor beta cx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505–3512.
150. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K et al. (2004). Serum phytoestrogens and prostate cancer risk in a nested case–control study among Japanese men. Cancer Sci 95: 65–71.
151. Pan M, Li Z, Yeung V, Xu RJ (2010). Dietary supplementation of soy germ phytoestrogens or estradiol improves spatial memory performance and increases gene expression of BDNF, TrkB receptor and synaptic factors in ovariectomized rats. Nutr Metab (Lond) 7: 75.
152. Park CE, Yun H, Lee EB, Min BI, Bae H, Choe W et al. (2010). The antioxidant effects of genistein are associated with AMP-activated protein kinase activation and PTEN induction in prostate cancer cells. J Med Food 13: 815–820.
153. Park J, Kim d H, Ahn HN, Song YS, Lee YJ, Ryu JH (2012). Activation of estrogen receptor by bavachin from Psoralea corylifolia. Biomol Ther (Seoul) 20: 183–188.
154. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu ZM et al. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 113: 1027–1037.
155. Patisaul HB, Jefferson W (2010). The pros and cons of phytoestrogens. Front Neuroendocrinol 31: 400–419.
156. Pearce ST, Jordan VC (2004). The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50: 3–22.
157. Penttinen P, Jaehrling J, Damdimopoulos AE, Inzunza J, Lemmen JG, van der Saag P et al. (2007). Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 148: 4875–4886.
158. Persson I (2000). Estrogens in the causation of breast, endometrial and ovarian cancers – evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74: 357–364.
159. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM et al. (1996). Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Canc Epidemiol Biomarkers Prev 5: 785–794.
160. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R et al. (2008). Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int 14: 6–12.
161. Prossnitz ER, Barton M (2011). The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7: 715–726.
162. Pudenz M, Roth K, Gerhauser C (2014). Impact of soy isoflavones on the epigenome in cancer prevention. Nutrients 6: 4218–4272.
163. Qin W, Zhu W, Shi H, Hewett JE, Ruhlen RL, MacDonald RS et al. (2009). Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutr Cancer 61: 238–244.
164. Qu XL, Fang Y, Zhang M, Zhang YZ (2014). Phytoestrogen intake and risk of ovarian cancer: a meta- analysis of 10 observational studies. Asian Pac J Cancer Prev: APJCP 15: 9085–9091.
165. Rebbeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M et al. (2007). A retrospective case–control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 120: 1523–1528.
166. Remely M, de la Garza AL, Magnet U, Aumueller E, Haslberger AG (2015a). Obesity: epigenetic regulation - recent observations. Biomol Concepts 6: 163–175.
167. Remely M, Lovrecic L, de la Garza AL, Migliore L, Peterlin B, Milagro FI et al. (2015b). Therapeutic perspectives of epigenetically active nutrients. Br J Pharmacol 172: 2756–2768.
168. Rickard DJ, Monroe DG, Ruesink TJ, Khosla S, Riggs BL, Spelsberg TC (2003). Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem 89: 633–646.
169. Rietjens IM, Sotoca AM, Vervoort J, Louisse J (2013). Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks. Mol Nutr Food Res 57: 100–113.
170. Rimoldi G, Christoffel J, Seidlova-Wuttke D, Jarry H, Wuttke W (2007). Effects of chronic genistein treatment in mammary gland, uterus, and vagina. Environ Health Perspect 115 (Suppl 1): 62–68.
171. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Womens Health (Larchmt) 16: 927–928.
172. Saarinen NM, Abrahamsson A, Dabrosin C (2010). Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 127: 737–745.
173. Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T, Kilpatrick ES et al. (2011). The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 96: 1442–1449.
174. Scarlata S, Miksicek R (1995). Binding properties of coumestrol to expressed human estrogen receptor. Mol Cell Endocrinol 115: 65–72.
175. Scherr FF, Sarmah AK, Di HJ, Cameron KC (2009). Degradation and metabolite formation of 17beta-estradiol-3-sulphate in New Zealand pasture soils. Environ Int 35: 291–297.
176. Schreihofer DA, Ma Y (2013). Estrogen receptors and ischemic neuroprotection: who, what, where, and when? Brain Res 1514: 107–122.
177. Setchell KD (1998). Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68: 1333S–1346S.
178. Setchell KD, Faughnan MS, Avades T, Zimmer-Nechemias L, Brown NM, Wolfe BE et al. (2003). Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr 77: 411–419.
179. Severson RK, Nomura AMY, Grove JS, Stemmermann GN (1989). A prospective-study of demographics, diet, and prostate-cancer among men of Japanese ancestry in Hawaii. Cancer Res 49: 1857–1860.
180. Shimazu T, Inoue M, Sasazuki S, Iwasaki M, Sawada N, Yamaji T et al. (2011). Plasma isoflavones and the risk of lung cancer in women: a nested case–control study in Japan. Canc Epidemiol Biomarkers Prev 20: 419–427.
181. Singh V, Sharma P, Capalash N (2013). DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 13: 379–399.
182. Soni M, Rahardjo TB, Soekardi R, Sulistyowati Y, Lestariningsih Y-UA et al. (2014). Phytoestrogens and cognitive function: a review. Maturitas 77: 209–220.
183. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Strom A, Gustafsson JA et al. (2008a). Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 105: 303–311.
184. Sotoca AM, Ratman D, van der Saag P, Strom A, Gustafsson JA, Vervoort J et al. (2008b). Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol 112: 171–178.
185. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl. Acids Res. 44: D1054–D1068.
186. Stafford HA (1997). Roles of flavonoids in symbiotic and defense functions in legume roots. Bot Rev 63: 27–39.
187. Stevens JF, Page JE (2004). Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry 65: 1317–1330.
188. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS (2004). Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145: 3473–3486.
189. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004). Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101: 1566–1571.
190. Struja T, Richard A, Linseisen J, Eichholzer M, Rohrmann S (2014). The association between urinary phytoestrogen excretion and components of the metabolic syndrome in NHANES. Eur J Nutr 53: 1371–1381.
191. Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H (2009). Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol Pharm Bull 32: 195–202.
192. Taku K, Melby MK, Takebayashi J, Mizuno S, Ishimi Y, Omori T et al. (2010). Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr 19: 33–42.
193. Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M (2012). Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause (New York, N.Y.) 19: 776–790.
194. Taylor CK, Levy RM, Elliott JC, Burnett BP (2009). The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev 67: 398–415.
195. Tempfer CB, Bentz EK, Leodolter S, Tscherne G, Reuss F, Cross HS et al. (2007). Phytoestrogens in clinical practice: a review of the literature. Fertil Steril 87: 1243–1249.
196. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, Huber JC (2009). Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 122: 939–946.e939.
197. ter Veld MG, Schouten B, Louisse J, van Es DS, van der Saag PT, Rietjens IM et al. (2006). Estrogenic potency of food-packaging-associated plasticizers and antioxidants as detected in ERalpha and ERbeta reporter gene cell lines. J Agric Food Chem 54: 4407–4416.
198. Thomas C, Gustafsson JA (2011). The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11: 597–608.
199. Thorp AA, Sinn N, Buckley JD, Coates AM, Howe PR (2009). Soya isoflavone supplementation enhances spatial working memory in men. Br J Nutr 102: 1348–1354.
200. Tiosano D, Paris F, Grimaldi M, Georgescu V, Servant N, Hochberg Z et al. (2014). Evidence of ERalpha and ERbeta selectivity and partial estrogen agonism in traditional Chinese medicine. Reprod Biol Endocrinol 12: 97.
201. Tokede OA, Onabanjo TA, Yansane A, Gaziano JM, Djousse L (2015). Soya products and serum lipids: a meta-analysis of randomised controlled trials. Br J Nutr 114: 831–843.
202. Trock BJ, Hilakivi-Clarke L, Clarke R (2006). Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98: 459–471.
203. Um MY, Ahn JY, Kim S, Kim MK, Ha TY (2009). Sesaminol glucosides protect beta-amyloid peptide-induced cognitive deficits in mice. Biol Pharm Bull 32: 1516–1520.
204. Valsta LM, Kilkkinen A, Mazur W, Nurmi T, Lampi AM, Ovaskainen ML et al. (2003). Phyto-oestrogen database of foods and average intake in Finland. Br J Nutr 89 (Suppl 1): S31–S38.
205. van der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, Keinan-Boker L, Rimm EB, Grobbee DE (2005). Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women. Circulation 111: 465–471.
206. van Die MD, Bone KM, Williams SG, Pirotta MV (2014). Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int 113: E119–E130.
207. Vanden Berghe W, Haegeman G (2008). Beneficial effects of soy isoflavones focus on epigenetic and anti-inflammatory effects. Agro Food Ind Hi Tech 19: 57–60.
208. Velentzis LS, Cantwell MM, Cardwell C, Keshtgar MR, Leathem AJ, Woodside JV (2009). Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies. Br J Cancer 100: 1492–1498.
209. Verheus M, van Gils CH, Kreijkamp-Kaspers S, Kok L, Peeters PH, Grobbee DE et al. (2008). Soy protein containing isoflavones and mammographic density in a randomized controlled trial in postmenopausal women. Canc Epidemiol Biomarkers Prev 17: 2632–2638.
210. Verkasalo PK, Appleby PN, Allen NE, Davey G, Adlercreutz H, Key TJ (2001). Soya intake and plasma concentrations of daidzein and genistein: validity of dietary assessment among eighty British women (Oxford arm of the European Prospective Investigation into Cancer and Nutrition). Br J Nutr 86: 415–421.
211. Wang Q, Li H, Tao P, Wang YP, Yuan P, Yang CX et al. (2011). Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: a case–control study in southwestern China. DNA Cell Biol 30: 585–595.
212. Wang S, Aarts JM, Evers NM, Peijnenburg AA, Rietjens IM, Bovee TF (2012). Proliferation assays for estrogenicity testing with high predictive value for the in vivo uterotrophic effect. J Steroid Biochem Mol Biol 128: 98–106.
213. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L (2008). The role of early life genistein exposures in modifying breast cancer risk. Br J Cancer 98: 1485–1493.
214. Watanabe S, Uesugi S, Kikuchi Y (2002). Isoflavones for prevention of cancer, cardiovascular diseases, gynecological problems and possible immune potentiation. Biomed Pharmacother 56: 302–312.
215. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA (2008). A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27: 1019–1032.
216. Wilson VS, Bobseine K, Gray LE Jr (2004). Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 81: 69–77.
217. Wu AH, Yu MC, Tseng CC, Pike MC (2008). Epidemiology of soy exposures and breast cancer risk. Br J Cancer 98: 9–14.
218. Wuttke W, Rimoldi G, Christoffel J, Seidlova-Wuttke D (2006). Plant extracts for the treatment of menopausal women: Safe? Maturitas 55: S92–S100.
219. Wuttke W, Jarry H, Seidlova-Wuttke D (2007). Isoflavones--safe food additives or dangerous drugs? Ageing Res Rev 6: 150–188.
220. Yan L, Spitznagel EL (2009). Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 89: 1155–1163.
221. Yan GR, Xiao CL, He GW, Yin XF, Chen NP, Cao Y et al. (2010). Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics 10: 976–986.
222. Yang WS, Va P, Wong MY, Zhang HL, Xiang YB (2011). Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. Am J Clin Nutr 94: 1575–1583.
223. Yao J, Zhao L, Mao Z, Chen S, Wong KC, To J et al. (2013). Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor beta-selective phytoSERM treatments. Brain Res 1514: 128–141.
224. Yoder SC, Lancaster SM, Hullar MAJ, Lampe JW (2015). Chapter 7 – Gut microbial metabolism of plant lignans: influence on human health A2 – Rio, Kieran TuohyDaniele Del. In: Diet-Microbe Interactions in the Gut. Academic Press: San Diego, pp. 103–117.
225. Zeng H, Chen Q, Zhao B (2004). Genistein ameliorates beta-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic Biol Med 36: 180–188.
226. Zhang XL, Shu XO, Gao YT, Yang G, Li Q, Li HL et al. (2003). Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. J Nutr 133: 2874–2878.
227. Zhang YB, Chen WH, Guo JJ, Fu ZH, Yi C, Zhang M et al. (2013). Soy isoflavone supplementation could reduce body weight and improve glucose metabolism in non-Asian postmenopausal women – a meta-analysis. Nutrition (Burbank, Los Angeles County, Calif) 29: 8–14.
228. Zhang GQ, Chen JL, Liu Q, Zhang Y, Zeng H, Zhao Y (2015). Soy intake is associated with lower endometrial cancer risk: a systematic review and meta-analysis of observational studies. Medicine 94: e2281.
229. Zhao L, Brinton RD (2009). In search of estrogen alternatives for the brain. In: Hormones, Cognition and Dementia: State of The Art and Emergent Therapeutic Strategies, Cambridge University Press: Cambridge pp. 93–100.
230. Zhao E, Mu Q (2011). Phytoestrogen biological actions on Mammalian reproductive system and cancer growth. Sci Pharm 79: 1–20.
231. Zhao L, Mao Z, Schneider LS, Brinton RD (2011). Estrogen receptor beta-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause (New York, N.Y.) 18: 1131–1142.